Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study

Completed · Not applicable

Conditions studied: Migraine

In brief

Preventive pharmacologic therapies for migraine aim to reduce attack frequency and duration and improve quality of life; however, their use, overall benefit and adherence are often limited. Remote electrical neuromodulation (REN) is a non-invasive FDA-cleared wearable device for acute and/or preventive migraine treatment. This study will evaluate the real-world efficacy and patient-reported outcomes of preventive REN use over 3 months in migraine patients.

Key facts

Study ID

NCT07487701

Run by

Theranica

People needed

332

Starts

2026-02-20

Expected to finish

2026-04-15

Last updated by the study team

2026-07-01

Who can join

Age: 8 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient with migraine
• Prescribed with a Nerivio REN device
• Treat with nerivio in a preventive -like manner over 3 consecutive months from sign up.

You may not qualify if…

• NA

Where it is running

• Theranica Bio-Electronics Inc — Bridgewater, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.